Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 01, 2021

SELL
$40.26 - $57.37 $257,221 - $366,536
-6,389 Closed
0 $0
Q2 2021

Jul 26, 2021

BUY
$54.88 - $79.29 $1,481 - $2,140
27 Added 0.42%
6,389 $363,000
Q1 2021

Apr 27, 2021

BUY
$70.65 - $96.76 $2,260 - $3,096
32 Added 0.51%
6,362 $476,000
Q4 2020

Jan 25, 2021

SELL
$58.41 - $89.06 $2,862 - $4,363
-49 Reduced 0.77%
6,330 $548,000
Q3 2020

Nov 06, 2020

BUY
$41.13 - $62.45 $262,368 - $398,368
6,379 New
6,379 $390,000
Q4 2019

Jan 21, 2020

SELL
$60.18 - $154.77 $256,065 - $658,546
-4,255 Closed
0 $0
Q3 2019

Oct 28, 2019

SELL
$140.29 - $189.96 $18,518 - $25,074
-132 Reduced 3.01%
4,255 $597,000
Q2 2019

Jul 29, 2019

BUY
$157.85 - $183.09 $106,548 - $123,585
675 Added 18.18%
4,387 $803,000
Q1 2019

Apr 30, 2019

BUY
$89.33 - $163.65 $27,602 - $50,567
309 Added 9.08%
3,712 $590,000
Q4 2018

Feb 01, 2019

BUY
$81.94 - $139.71 $45,722 - $77,958
558 Added 19.61%
3,403 $326,000
Q3 2018

Jan 04, 2019

SELL
$138.11 - $169.04 $409,081 - $500,696
-2,962 Reduced 51.01%
2,845 $402,000
Q3 2018

Nov 14, 2018

BUY
$138.11 - $169.04 $802,004 - $981,615
5,807 New
5,807 $0

Others Institutions Holding SAGE

About Sage Therapeutics, Inc.


  • Ticker SAGE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,422,300
  • Market Cap $326M
  • Description
  • Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...
More about SAGE
Track This Portfolio

Track Janney Capital Management LLC Portfolio

Follow Janney Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Janney Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Janney Capital Management LLC with notifications on news.